The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms Natasha C. Gunawardana,

Slides:

Advertisements

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Advertisements

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy Ravi S. Swamy, MD, Neha Reshamwala,

The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge Grant C. Nicholson, BSc, Harsha H. Kariyawasam,

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion William T. Barchuk, MD, Anne Marie Salapatek,

Allergen immunotherapy: A practice parameter third update

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE Elizabeth A. Erwin,

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy Michael Kulis, PhD, Katie.

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood Zaraquiza Zolkipli, MSc,

Oral steroids and doxycycline: Two different approaches to treat nasal polyps Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies

Is 9 more than 2 also in allergic airway inflammation?

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy Robert A.

Facilitated antigen presentation and its inhibition by blocking IgG antibodies depends on IgE repertoire complexity Jens Holm, PhD, Nicholas Willumsen,

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Ryan S. Thwaites, PhD, Natasha C

Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract Sheila M. Amar, MD, Ronald.

Hendrik Nolte, MD, PhD, David I

Mohamed H. Shamji, PhD, Janice A. Layhadi, MSc, Guy W

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

IL-5 T-cell responses to house dust mite are associated with the development of allergen-specific IgE responses and asthma in the first 5 years of life

Reply Journal of Allergy and Clinical Immunology

Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti–IL-4: A randomized controlled trial Adam M. Chaker, MD, Mohamed H. Shamji,

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Decreases in human dendritic cell–dependent TH2-like responses after acute in vivo IgE neutralization John T. Schroeder, PhD, Anja P. Bieneman, BS, Kristin.

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion William T. Barchuk, MD, Anne Marie Salapatek,

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial Hendrik.

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Lisa G. Wood, PhD, Manohar L. Garg, PhD, Peter G. Gibson, MBBS

Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy Eva Wollmann,

John A. Eckman, MD, Patricia M

What is an “eosinophilic phenotype” of asthma?

Enhanced CD46-induced regulatory T cells suppress allergic inflammation after Dermatophagoides pteronyssinus–specific immunotherapy Yi-Giien Tsai, MD,

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

House dust mite sublingual immunotherapy: Results of a US trial

Association between specific timothy grass antigens and changes in TH1- and TH2-cell responses following specific immunotherapy Véronique Schulten, PhD,

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis Karl-Christian Bergmann, MD, Pascal Demoly,

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years Ronald Dahl, MD,

Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy Padmaja Subbarao, MD, MSc, Sandra C. Dorman,

The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge Grant C. Nicholson, BSc, Harsha H. Kariyawasam,

Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract Anil Nanda, MD, Maeve O'Connor, MD,

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 Kandace Bonner,

Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber

Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite–induced allergic.

Peanut oral immunotherapy decreases IgE to Ara h 2 and Ara h 6 but does not enhance sensitization to cross-reactive allergens Riikka Uotila, MD, Anna.

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

Alvaro A. Cruz, MD, Robert M

Nasal challenge with allergen leads to maxillary sinus inflammation

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy Kayhan T. Nouri-Aria, PhD, FRCPath, Charles.

Päivi M. Salo, PhD, Samuel J. Arbes, DDS, MPH, PhD, Patrick W

Macrolide antibiotics and asthma treatment

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy– treated mother Sabine Flicker, PhD, Katharina Marth, MD, Heinz.

Effect of grass sublingual tablet immunotherapy is similar in children and adults: A Bayesian approach to design pediatric sublingual immunotherapy trials

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding Sven.

Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization Edwin H. Kim, MD, J. Andrew Bird, MD, Michael Kulis,

The GILL study: Glycerin-induced local reactions in immunotherapy

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Systemic responses after bronchial aspirin challenge in sensitive patients with asthma Joanna S. Makowska, MD, PhD, Janina Grzegorczyk, PhD, Barbara Bienkiewicz,

Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response Meri K Tulic, PhD, Pierre-Olivier Fiset,

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

The Editors' Choice Journal of Allergy and Clinical Immunology

Presentation transcript:

The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms Natasha C. Gunawardana, MBBS, Qing Zhao, PhD, Leonidas N. Carayannopoulos, MD, PhD, Kuenhi Tsai, PhD, Vladislav A. Malkov, PhD, Diana Selverian, BSN, Graham Clarke, PhD, Tim Mant, MB, Brent D. Butts, PhD, Kaare Lund, PhD, Trevor T. Hansel, FRCPath, PhD, Hendrik Nolte, MD, PhD Journal of Allergy and Clinical Immunology Volume 141, Issue 2, Pages 785-788.e9 (February 2018) DOI: 10.1016/j.jaci.2017.08.016 Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Effect of 12 SQ-HDM treatment on serum antibody-related parameters (A) and NAC-induced symptoms (B). Values are least squares geometric mean ± 95% CI for IgG4, and least squares mean ± 95% CI for IgE-BF. *P < .05 for difference in ratio of geometric mean (IgG4) or change from baseline (IgE-BF) vs placebo. †Percent change from baseline NAC at 15 minutes. ‡P = .02 vs placebo. mgA/L, Milligram antibody per liter. Journal of Allergy and Clinical Immunology 2018 141, 785-788.e9DOI: (10.1016/j.jaci.2017.08.016) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Effect of 12 SQ-HDM treatment on NAC-induced IL-5 concentrations (A) in mucosal lining fluid and nasal cell mRNA markers (B). Error bars for IL-5 concentrations indicate minimum and maximum values. Fold changes are estimated and the fold change at baseline is assumed to be the same for both treatment groups. Journal of Allergy and Clinical Immunology 2018 141, 785-788.e9DOI: (10.1016/j.jaci.2017.08.016) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 A, Study design. B, Sampling schedule at weeks −2, 8, and 12. Journal of Allergy and Clinical Immunology 2018 141, 785-788.e9DOI: (10.1016/j.jaci.2017.08.016) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E2 The TNSS during early and late phases of NACs at weeks −2, 8, and 12. Percentages indicate change from baseline. *P ≤ .05 for change from baseline versus placebo. Journal of Allergy and Clinical Immunology 2018 141, 785-788.e9DOI: (10.1016/j.jaci.2017.08.016) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E3 Subject-level protein concentrations in nasal mucosal lining fluid at 1 hour pre-NAC, 15 minutes post-NAC (except TARC), and 6.5 hours post-NAC at weeks −2, 8, and 12 for IL-5 (A), IL-13 (B), and TARC (C). BLOQ, Below limit of quantitation. Journal of Allergy and Clinical Immunology 2018 141, 785-788.e9DOI: (10.1016/j.jaci.2017.08.016) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E3 Subject-level protein concentrations in nasal mucosal lining fluid at 1 hour pre-NAC, 15 minutes post-NAC (except TARC), and 6.5 hours post-NAC at weeks −2, 8, and 12 for IL-5 (A), IL-13 (B), and TARC (C). BLOQ, Below limit of quantitation. Journal of Allergy and Clinical Immunology 2018 141, 785-788.e9DOI: (10.1016/j.jaci.2017.08.016) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E4 Correlations between mRNA markers. Journal of Allergy and Clinical Immunology 2018 141, 785-788.e9DOI: (10.1016/j.jaci.2017.08.016) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions